Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations

TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed AML patients with diverse mutationsSafety continues to be a notable hallmark of TUS-based therapies100% response rate (CR/CRh) at the two higher dose levels (80 and 120 mg TUS dose)CR/CRh observed in FLT3 wildtype subjects, representing ~70% of AML patientsCR/CRh observed in AML with TP53/complex karyotype, RAS, and MDS-related mutations SAN DIEGO and TORONTO, Dec. 06, 2025 (GLOBE NEWSWI ...